scholarly journals Reductions in Methicillin-resistant Staphylococcus aureus, Clostridium difficile Infection and Intensive Care Unit–Acquired Bloodstream Infection Across the United Kingdom Following Implementation of a National Infection Control Campaign

2019 ◽  
Vol 70 (12) ◽  
pp. 2530-2540 ◽  
Author(s):  
Jonathan D Edgeworth ◽  
Rahul Batra ◽  
Jerome Wulff ◽  
David Harrison

Abstract Background Methicillin-resistant Staphylococcus aureus (MRSA) and Clostridium difficile infections declined across the UK National Health Service in the decade that followed implementation of an infection control campaign. The national impact on intensive care unit (ICU)-acquired infections has not been documented. Methods Data on MRSA, C. difficile, vancomycin-resistant Enterococcus (VRE), and ICU–acquired bloodstream infections (UABSIs) for 1 189 142 patients from 2007 to 2016 were analyzed. Initial coverage was 139 ICUs increasing to 276 ICUs, representing 100% of general adult UK ICUs. Results ICU MRSA and C. difficile acquisitions per 1000 patients decreased between 2007 and 2016 (MRSA acquisitions, 25.4 to 4.1; and C. difficile acquisitions, 11.1 to 3.5), whereas VRE acquisitions increased from 1.5 to 5.9. There were 13 114 UABSIs in 1.8% of patients who stayed longer than 48 hours on ICU. UABSIs fell from 7.3 (95% confidence interval [CI], 6.9–7.6) to 1.6 (95% CI, 1.5–1.7)/1000 bed days. Adjusting for patient factors, the incidence rate ratio was 0.21 (95% CI, 0.19–0.23, P < .001) from 2007 to 2016. The greatest reduction, comparing rates in 2007/08 and 2015/16, was for MRSA (97%), followed by P. aeruginosa (81%), S. aureus (79%) and Candida spp (72%), with lower reductions for the coliforms (E. coli 57% and Klebsiella 49%). Conclusions Large decreases in ICU-acquired infections occurred across the UK ICU network linked with the first few years of a national infection control campaign, but rates have since been static. Further reductions will likely require a new intervention framework.

2019 ◽  
Vol 6 (Supplement_2) ◽  
pp. S856-S856
Author(s):  
Rahul Batra ◽  
Jonathan Edgeworth ◽  
Jerome Wulff ◽  
David Harrison

Abstract Background Methicillin-Resistant Staphylococcus aureus (MRSA) and C. difficile infection have reduced across the UK National Health Service in the last decade following implementation of an infection control campaign. The national impact on hospital-acquired infections in the ICU however has not been comprehensively documented. Methods Data on MRSA, C. difficile, vancomycin-resistant Enterococcus (VRE) and ICU-acquired bloodstream infection (UABSIs) were analyzed from 1,189,142 consecutive patients from 2007 to 2016 recorded prospectively and standardized by highly trained assessors. Initial coverage was 139 ICUs increasing to 275 ICUs representing 100% of general, adult UK ICUs. Results ICU MRSA and C. difficile admissions and acquisitions per 1000 patients decreased between 2007 and 2012 (MRSA admissions 38.8 to 13.1; acquisitions 25.4 to 4.1; C. difficile admissions 10.6 to 4.2; acquisitions 11.1 to 3.5), whereas VRE admissions and acquisitions increased from 1.9 to 5.3 and 1.5 to 5.9, respectively. There were 13,114 UABSIs in 1.8% patients staying >48 hours. UABSIs fell from 7.3 (95% CI 6.9–7.6) to 1.6 (95% CI 1.5–1.7)/1,000 bed-days between 2007 and 2012. Adjusting for patient admission and ICU factors the IRR was 0.21 (95% CI 0.19–0.23, P < 0.001) from 2007 to 2016. Reductions in UABSIs were seen for all main organisms excluding VRE with greatest reductions for MRSA (97%), Pseudomonas aeruginosa (80%), S. aureus (77%) and Candida spp. (71%) but lower reductions for E. coli (54%) and Klebsiella (42%). Conclusion Large decreases in ICU-acquired infections occurred across the UK ICU network between 2007 and 2012 linked with the first few years of the national infection control campaign, but rates have been static since. Further reductions in ICU will likely require a new intervention framework. Disclosures All authors: No reported disclosures.


Sign in / Sign up

Export Citation Format

Share Document